Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05578872 · ClinicalTrials.gov registry record · Phase 1
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
A Phase 1 study, sponsored by Anaveon.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05578872 is a Phase 1 study that has completed, run by Anaveon. The registered enrollment target is 29 participants.
The verdict
NCT05578872, a Phase 1 study, has completed, sponsored by Anaveon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma. The study has 3 parts. Part 1 to evaluate ANV419 in monotherapy and Parts 2 and 3 to evaluate ANV419 in combination with anti-PD1 antibody or anti-CTLA4 antibody. Parts 2 and 3 were not initiated, as the prespecified efficacy criteria to graduate to Part 2 were not met at the interim analysis of Part 1.
Interventions
- DRUG ANV419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05578872
The ClinicalTrials.gov registry entry for NCT05578872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anaveon, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ANV419 is the first listed.
NCT05578872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05578872 about?
NCT05578872 is a clinical study titled "A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).". The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma. The study has 3 parts. Part 1 to evaluate ANV419...
What is the current status of trial NCT05578872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-12-16. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT05578872?
The interventions under investigation include: ANV419 (DRUG).
Who is sponsoring clinical trial NCT05578872?
This trial is sponsored by Anaveon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.